FG-4592 - Roxadustat | ASP 1517

Based on 259 reference(s) in Google Scholar 9 10 259

Axon 2588

CAS [808118-40-3]

MF C19H16N2O5
MW 352.34

  • Purity: 99%
  • Soluble in 0.1N NaOH(aq) and DMSO

FG-4592

Description

New-generation oral HIF-PHD inhibitor (IC50 value 591 nM for inhibition of PHD2 in a fluorescence polarization assay) for the treatment of anemia in patients with chronic kidney disease (CKD) by promoting erythropoiesis. FG 4592 (Roxadustat) treatment significantly inhibited tert-Butyl hydroperoxide (TBHP)-induced apoptosis and increases the survival of neuronal PC-12 cells by stabilization of HIF-1α. FG 4592 is also shown to inhibit Fat Mass and Obesity Associated Protein (FTO; IC50 value 9.8 μM).

KEYWORDS: FG-4592 | supplier | HIFα-PHD inhibitor | Roxadustat | ASP 1517 | FG4592 | ASP1517 | CAS [808118-40-3] | Hypoxia-signaling cascade | PHD-2 (HIF1) | Inhibitor | PHD2 | anemia | chronic kidney disease | CKD | erythropoiesis | survival | HIF-1α | Fat | Obesity Associated Protein | FTO

Order
Size Unit Price Stock
10 mg €55.00 In Stock
50 mg €175.00 In Stock
100 mg €325.00 In Stock
Need more? Bulk Inquiry

The purity of Axon Ligands™ is confirmed by HPLC-MS, 1H-NMR and/or microanalysis. Analytical data are available upon request.

Caution: Axon Ligands™ are not fully tested. They are for research purposes only! Not for human consumption!

Please wait...